BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Hematopoietic cell
,
Quercetin
,
rs6983267
,
SNCA
,
Response to oxidative stress
,
Neuron
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
medullary carcinoma
Summary
General Info
Curated Studies
Most Correlated Studies
OMIM - Malignant neoplasms
OMIM - Cancer
OMIM - Thyroid disease
Thyroid adenomas and carcinomas expression profiles
Medullary thyroid cancer TT cell line treated with FAK inhibitors - Y15 or PF04554878
Explore Curated Studies Results
Literature
Most Relevant Literature
A Case of Medullary Carcinoma of the Colon].
Collecting duct carcinoma and renal medullary carcinoma in the age of new therapies].
Clinical Evolution of Sporadic Medullary Thyroid Carcinoma With Biochemical Incomplete Response Afte…
Management of medullary carcinoma of the thyroid: a review.
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Medullary Colonic Carcinoma
Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ